Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.
Tumor necrosis factor-alpha (TNF-alpha) is a chemokine secreted by T cells which is thought to play a critical role in the pathophysiology of psoriasis. The monoclonal antibody, infliximab, complexes with TNF-alpha, rendering it inactive. A recent clinical trial has reported the clinical benefit and safety of infliximab in moderate to severe plaque psoriasis. We report a case of rapid response and clinical benefit using infliximab in severe pustular psoriasis of von Zumbusch.
Department of Dermatology and Cutaneous Surgery, University of Miami, 1444 NW 9th Avenue, Miami, FL 33136, USA. dermatology.department@hcahealthcare.com
Meggan R
MR
Newland
Andrew
A
Weinstein
Francisco
F
Kerdel
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011930:Reaction Time / Q000502:physiology; D012720:Severity of Illness Index; D013997:Time Factors
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab